Similar to the AML patient application, we observed significant differences in the ex vivo drug sensitivities between the patient-specific treatments predicted to be either effective or ineffective when assessed in patient-derived PAX8+ cells (p < 0.001, Wilcoxon test; Fig. 3h). Here, PAX8 is linked to acute myeloid leukemia.